Abstract: Nicotine addiction and other forms of drug addiction continue to be significant public health problems in the United States and the rest of the world. Accumulated evidence indicates that brain nicotinic acetylcholine receptors (nAChRs) are a heterogenous family of ion channels expressed in the various parts of the brain. A growing body of preclinical studies suggests that brain nAChRs are critical targets for the development of pharmacotherapies for nicotine and other drug addictions. In this review, we will discuss the nAChR subtypes, their function in response to endogenous brain transmitters, and how their functions are regulated in the presence of nicotine. Furthermore, we will discuss the role of nAChRs in mediating nicotine-induced addictive behavior in animal models. Additionally, we will provide an overview of the effects of nicotine and nicotinic compounds on the mesolimbic dopamine system, part of the reinforcement/reward circuitry of the brain, as an example of the neurochemical basis of nicotine addiction and other drug addictions. An appreciation of the complexity of nicotinic receptors and their regulation will be necessary for the development of nicotinic receptor modulators as potential pharmacotherapy for drug addiction.
INTRODUCTION
Volition, an intangible product of the brain, emerges from the central nervous system in the form of action potentials and is made into physical reality through the effect of the neurotransmitter acetylcholine on the nicotinic receptors of our neuromuscular junctions. Nicotinic acetylcholine receptors (nAChRs) were at the core of our earliest understandings of synaptic function, knowledge fostered by pioneers like Charles Sherrington and Bernard Katz. Likewise, study of the nAChR of the neuromuscular junction was carried forward through the earliest beginnings of modern molecular neurobiology, being the first neurotransmitter receptor to be isolated, cloned, and analyzed at the level of its single channel currents. Ironically, although it is glutamate, not acetylcholine, that plays the major role as mediator of fast excitatory neurotransmission in the brain, the principles obtained from the study of the neuromuscular junction remain the conceptual underpinnings we apply to studies of synaptic function in the brain. Even more ironic is the fact that in many people the receptors of the brain, which are homologous to those of the neuromuscular junction, subvert volition by being the mediators of nicotine addiction and dependence, thus preventing people who have the desire to quit smoking from so doing. In this review we will discuss the nAChR subtypes found in the brain, how they function normally in response to endogenous transmitters, and how their functions are altered in the presence of nicotine. We will discuss what is known about the molecular substrates of nicotine addiction and also the scope of the unanswered questions in the field. Additionally, we will discuss the hypothesis that since the nicotine receptors of the brain are at the core of nicotine addiction, they are also a key target to be addressed for the treatment and relief of nicotine addiction, and possibly other drug dependencies.
It is eminently approachable to study the pharmacology of single nicotinic receptor subtypes, due to the molecular cloning of the relevant genes, but it is not so easy to interpret such information in the context of brain function and the complex underpinnings of addictive behavior. Moreover, a major obstacle for understanding how to treat drug addiction is the difficulty in separating the roles played by the primary reinforcing qualities of a drug and subsequent effects which may modify use, such as physical dependence. The nAChRs of the brain may well be involved in both reinforcement and dependence aspects of nicotine addiction, but the specific receptor subtypes and/or their locations in the brain may differ. Likewise, the functional modality of the drugs, which might be best-suited for targeting these two facets of addiction, could well be different. For example, while a nAChR antagonist might be useful to block the short-term reinforcement derived from nicotine administration; such a drug would precipitate withdrawal in a dependent individual. Nonetheless, if reinforcement and physical dependence are due to distinctly different nAChR subtypes, then a truly se-lective antagonist could blunt the reinforcement without precipitating withdrawal.
OVERVIEW OF NICOTINIC RECEPTORS
The nAChRs form a family of ligand-gated cation channels that are predominantly excitatory neurotransmitter receptors on muscles and nerves in the peripheral and central nervous systems. These receptors belong to a gene super family of homologous receptors including -aminobutyric acid (GABA), glycine and serotonin [1] [2] [3] [4] , known as Cysloop receptors due to the presence of a conserved sequence containing a pair of cysteines separated by 13 residues and linked by a disulfide bridge ( [5] , reviewed in [3, 6] ). The nAChR family is comprised of two groups: muscle receptors, localized at the skeletal neuromuscular junction where they mediate neuromuscular transmission, and the neuronal receptors, which are distributed throughout both the peripheral and central nervous systems. Muscle-type nAChR are pentameric complexes with four subunits; 1 , 1 , and in fetal receptors and 1 , 1 , and in the adult forms, with two 1 subunits in each pentamer.
Currently, twelve neuronal nAChR subunits have been identified and cloned. Based on the presence or absence of a key functional element of the muscle-type 1 subunit, a pair of adjacent or viscinal cysteines, they have been classified as either alpha subunits ( 2 -10) or beta subunits ( 2 -4), respectively [1, [7] [8] [9] . These subunits assemble into functional pentameric receptors, which can be further subdivided into two subtypes of neuronal nAChRs. Heteromeric receptors are assembled from both alpha ( 2 6 ) and beta subunits. The functional properties of such heteromeric receptors depend on both the specific and subunits within the receptor complex [10] and the ratio of the subunits [11] [12] [13] [14] . The second major type of neuronal nAChRs functions without incorporation of a beta subunit. The principal representative of this class is the 7 receptor, which is believed to normally function as a homopentamer of 7 subunits. Receptors containing 9 and/or 10 subunits are usually classified with 7. However, they are probably not strictly homomeric, but rather heteromeric complexes of the two alphatype subunits. Likewise, it has been reported that in chick retina [15] and optic lobe [16] the 7 subunit forms heteromeric complexes with 8 subunits (which have not been identified in mammals). The 10 nAChR subunit, which is similar to the 9 subunit with regard to amino acid sequence, sharing about 58% identity [17] , shows no functional expression when injected alone ( [17, 18] ; reviewed in [1] ). However, functional nAChRs have been obtained when 10 was coexpressed with 9 in Xenopus oocytes. The co-expression increased the size of the 9-mediated responses and modulated function [17, 18] .
As noted above, nAChR have a pentameric structure consisting of five membrane-spanning subunits which surround a central ion channel [19] . All nAChR subunits share a similar hydropathy profile, with a large N-terminal hydrophilic extracellular domain that contains elements of the AChbinding sites, four hydrophobic transmembrane segments denoted M1, M2, M3, and M4, a variable cytoplasmic domain between M3 and M4, and a short extracellular carboxylic terminal [20] . The pore of the channel is formed by amino acids of the M2 and top third of M1 transmembrane domains of each subunit [3] . The channel pore consists of a tunnel of negative electrostatic potential formed by a ring of glutamic acid residues, which allow the entry of sodium and potassium cations [21] and in some cases, calcium. The M3 and M4 segments contribute to the hydrophobic core of the protein and interact with the lipid bilayer.
Torpedo, skeletal muscle, and heteromeric neuronal nAChRs contain two ACh binding sites [22, 23] . Both sites have to be occupied by ACh or other nicotinic agonists to induce channel activation with highest probability (for review see [24] ). Photo-affinity experiments carried out with the nAChR from skeletal muscle have shown that the ligandbinding sites are at the interface between the alphas and their adjacent / and subunits [3, [25] [26] [27] . The subunit contributes the "principal" component of the binding site and the adjacent subunit has a "complementary" surface [28] . In the subunit, residues in three distinct regions along the linear chain converge at the binding site; these regions are denoted as loops A, B, and C (reviewed by [24] ). As noted above, subunits are defined by the presence of a cysteine pair at position 192 and 193 (Torpedo receptor sequence numbers) within the C-loop, which contribute to the ACh binding sites [5, 29] . The complementary subunit ( , , or in muscle type receptors) contributes three elements referred to as loops: D, E, and F. The loops that form the ligand-binding site include conserved residues, many of which have aromatic side chains (e.g. tyrosine and tryptophan) that are suggested to make cation-interactions with agonists [20] .
Neuronal Nicotinic Receptors
Neuronal nAChRs are distributed throughout the central and peripheral nervous systems. While they are the primary mediators of synaptic transmission in autonomic ganglia, in the brain they modulate the signals mediated by other neurotransmitters [30, 31] . Elucidation of the functional and structural characteristics of neuronal nAChRs has been difficult due to their relatively low abundance and their heterogeneous distribution in various tissues [32] . Many properties of the heteromeric neuronal nAChR, such as their ion selectivity and gating properties, are similar to their muscle counterparts. The overall amino acid homology between the genes coding for the neuronal subunits and muscle genes from the same species is about 40-55% [4] . The homology is higher (~100%) in the membrane-spanning regions M1-M3 and in certain regions of the N-terminal domain; however, the amino acid sequence of the cytoplasmic domain between M3 and M4 transmembrane segments is quite variable [4] . The identification of an extensive homology among the numerous nAChR subunit genes indicates that they share a common ancestor, which was later demonstrated by phylogenetic tree reconstitution [8] . The reconstituted phylogenetic tree places an early divergence of other subunits from an ancestral form that is most closely related to the 9 subunit [8, 33] .
However, the neuronal nAChRs are clearly different from the skeletal muscle nAChRs and are distinguished by their great diversity of both sequence and function [4, 34] . Neuronal nAChRs are also distinguished from muscle type nAChRs by having larger calcium permeability [35] [36] [37] [38] . The pCa 2+ /pNa + for neuronal nAChRs ranges from 15 to 0.5, with the "homomeric" subtypes like 7 having the highest calcium permeability, while the muscle nAChR displays a pCa 2+ /pNa + of ~0.2 [37, [39] [40] [41] . The permeation of Ca 2+ through nAChR channels could activate intracellular cascades or other ion channels and potentially induce changes in the phosphorylation states of specific nAChR subunits [37, [42] [43] [44] . Moreover, intracellular cascades triggered by Ca 2+ responses generated after nAChR activation could also underlie neuronal processes ranging from learning and memory to addiction and neuroprotection [45] .
Much of the information about the functional significance of subunit composition of neuronal nicotinic receptors has come from studies of nAChR subunit expression in heterologous systems. Individual injection of 2, 3, 4, 2, or 4 subunits into the appropriate expression system did not produce any functional response, except for 4, which elicited small depolarizations in response to high ACh concentrations in about one third of the trials ( [46] , reviewed in [4] ). When any of the 2-4 subunits are expressed in pairwise combinations with 2 or 4, functional receptors are assembled (i.e. 2 2, 2 4, 3 2, 3 4, 4 2, 4 4) differing in electrophysiological and pharmacological properties [46] [47] [48] . As in the case of the muscle-type nAChR, for the heteromeric neuronal receptors, alpha subunits contain primary elements of the ACh binding sites and the non-alpha (i.e. beta) subunits contain the complimentary domains. Several studies have revealed the pivotal role of subunits on the dissociation rate of agonist and antagonist from the receptor as well as the opening rate of agonist bound receptor [49, 50] , reviewed in [22] . The assembly of three or more neuronal subunit types can also form functional heteromeric nAChR [30, 51] . For example, the 5 subunit cannot form functional receptors in combination with 2 or 4. However, when expressed with other functional subunit combinations (such as 4 and 2, 3 and 2, or 3 and 4) the 5 subunit is incorporated into the functional nAChR [51, 52] and plays a role in determining the properties of the receptors. Receptors containing 5 have been found in vivo; for example, some nAChRs in chick ciliary ganglion neurons have been shown to contain 3 2 4 5 subunits, with most likely two 3 subunits in each pentamer [53] . Although classified as an alpha subunit based on sequence homology, 5 when present in a pentameric complex does not appear to contribute to an agonist binding site and is therefore designated a "structural subunit" [54] , as is the 1 subunit of muscle nAChR. The same applies to the 3 subunit, which only forms functional nicotinic receptors when co-expressed with at least two other subunit types [55] . The 6 subunit has been shown to form functional nAChRs in combination with 4. Higher levels of expression were detected when 6 was co-expressed with at least two other types of subunits, including 3 ( [56, 57] , reviewed in [58] ). Also, since the areas of 6 expressions include dopamine-rich areas of the brain, such as the substantia nigra and the ventral tegmental area (VTA) [32, 59, 60] , 6* receptors have been hypothesized to be a good candidate for therapeutic interventions related to nicotine reinforcement and dependence [61] .
Skeletal muscle nAChR has provided an important model for the study of subunit stoichiometry, organization and conformational changes. Although the muscle subunit stoichiometry is well understood, much is less known about the stoichiometry of heteromeric neuronal nAChRs. Previous studies have proposed that the subunit stoichiometry of the 4 2 expressed in oocytes is ( 4) 2 ( 2) 3 [62, 63] . Various functional studies, however, suggest that ( 4) 2 ( 2) 3 is not the only stoichiometry present in cells expressing this nAChR subtype. When the relative levels of expression of the 4 and 2 were varied by nuclear injection of three : ratios into Xenopus oocytes, different sensitivities to acetylcholine and d-tubocurarine were obtained using voltage clamp recording [11] . These results suggest that the subunit stoichiometry of functional heteromeric 4 2 nAChR is not limited to ( 4) 2 ( 2) 3 . This finding was strongly supported by studies that have controlled subunit stoichiometry with subunit concatamers of human 4 and 2 nAChR subunits [13] . Furthermore, work by Nelson et al. [12] reported two functional types of 4 2 nAChR expressed in human embryonic kidney (HEK) cells. These investigators found that the predominant subunit stoichiometry of 4 2 nAChR expressed in HEK cells was ( 4) 3 ( 2) 2 , yet overnight nicotine exposure increased the proportion of nAChRs with a ( 4) 2 ( 2) 3 stoichiometry. Additionally, López-Hernández et al. suggested that the functional state of the 4 2 nAChR expressed into Xenopus oocytes is regulated by subunit ratio [14] . The authors showed that oocytes expressing different ratios of 4 and 2 subunits exhibited significant differences in the ACh-and nicotine-induced macroscopic peak currents and in the half maximal response to ACh. Also they demonstrated that as the ratio of 2: 4 injected increased, the desensitization of 4 2 nAChR becomes more evident. Moreover, only oocytes expressing 4: 2 subunit ratio of 2:3 exhibited up-regulation after chronic nicotine exposure. Collectively, that data revealed the critical influence of subunit ratio in the nicotine-induced desensitization and upregulation of 4 2 nAChRs [14] .
As noted previously, the neuronal nAChR subunits 7, 8, or 9 can form functional homopentamers [36, [64] [65] [66] . Due to the composition of the homomeric neuronal nAChR, oligomers constituted by five subunits with each having both the principal and complementary elements of an ACh binding site, five identical binding sites are suggested to exist in these receptor proteins [67] . The homomeric nicotinic receptors are characterized by sensitivity to -bungarotoxin, and two other properties, which distinguish the -bungarotoxin-sensitive neuronal nAChRs from the nonsensitive heteromeric nAChRs; these are their very rapid rate of desensitization at higher agonist concentrations and higher levels of calcium permeability [36, 65, 66, 68] . The high Ca 2+ permeability of 7, 8, and 9 nAChRs may allow these receptors to generate a calcium signal that serves as a second messenger in cells to alter several cellular processes [32] . Additionally, 7 displays voltage-sensitive blockade of the ion channel by Mg 2+ and intracellular polyamines so that they do not conduct current when the membrane is depolarized ( [68] , reviewed in [32] ).
Localization
Ligand binding, immunoprecipitation, and immunopurification experiments have helped in the isolation of native nAChRs; however, the full scope of their diversity has yet to be determined, due in part to the lack of subtype-selective ligands and antibodies [1, 4, 7, 69] . Additionally, singlechannel studies have shown that there is a molecular diversity of nAChR subtypes in individual cells. A single given neuron may have three or more distinct nAChR channel types, and the array of channel types in a given cell will change over time with development and maturation [70] . In spite of this tremendous potential for diversity, numerous general observations can be made.
The 2 nAChR subunit mRNA expression is rather limited in rodents; immunoprecipitation experiments have shown the presence of 2-containing receptors in rat retina and interpenduncular nucleus, and it also has been detected in chick optic lobe [reviewed by 7] . Higher levels of 2 have been detected in monkey [71] and human cortex [69] . The 3-containing nAChRs are predominantly located on autonomic neurons and are less abundant in the brain [4, 53, 72] . In vitro and in vivo studies using specific inhibitors of nAChRs demonstrate that ganglionic transmission in cardiac parasympathetic neurons is mediated by 3 2 and 3 4 with little contribution of 7 receptors [73] . Nicotinic receptors composed of 3 and 4 are involved in ganglionic transmission in the bladder [74] .
The most abundant nAChRs in the central nervous system (CNS) are 4 2*, which contain both 4 and 2 subunits and sometimes additional subunits (denoted by the asterisk). These receptors account for > 90% of the high affinity nicotine binding sites in the brain [75, 76] . The 4 and 2 subunits are co-localized in brain areas such as thalamic nuclei, isocortex, dorsomedial hypothalamic nucleus, and the ventral midbrain [7, 69] . Alpha7 nAChRs are highly expressed in the brain and are also present in autonomic ganglia [76, 77] . In the brain, 7 nicotinic receptors are predominantly located in the hippocampus, cortex, and subcortical limbic regions [7, 69] . Expression of otherbungarotoxin-sensitive nAChRs is more limited; 9 homomers and 9/ 10 heteromers have been found in mammalian vestibular and cochlear hair cells [18, 65] . Neuronal nAChRs containing 6 are thought to exist in relatively low amounts in limited areas of the brain, but as already noted, areas of 6 expression include dopamine-rich areas of the brain; hence 6* receptors may be good candidates for therapeutic interventions related to nicotine reinforcement and dependence. As mentioned earlier, neither 5 nor 3 subunits can form functional receptors when co-exprssed with only one other or subunit, thus suggesting that 5 and 3 do not directly contribute to the formation of the agonist binding site and are thus considered "auxiliary or structural" subunits [51, 55] , reviewed in [1] . However although these subunits are not apparently necessary to yield functional receptors they can influence the pharmacological properties of the particular nicotinic receptor subtype as for example, 5 when co-expressed with 3 differentially altered the sensitivity to ACh depending on whether 2 or 4 was present [51] . Expression of 5 has been found in both peripheral and central nervous systems; particularly in CNS high levels have been detected in hippocampus (CA1 area), interpeduncular nucleus, VTA, and substantia nigra compacta [78] [79] [80] . Recent evidence has demonstrated that 5-containing receptors can also mediate nicotine induced behaviors; 5 mutant mice only differ from wild-type in terms of their nicotine-induced seizures and hypolocomotion, with null mice being more resistant to nicotine effects than wildtype [81] . Nicotinic receptors have been also been detected in non-neuronal tissue such as epithelial cells [82] [83] [84] [85] , lymphocytes [86] [87] [88] , astrocytes [89] [90] [91] , microglia [92] , and macrophages [93] .
Function
While skeletal muscle nAChRs function in a classical postsynaptic manner, little evidence about postsynaptic neuronal nicotinic receptors has been demonstrated aside from the essential roles they play in autonomic ganglia, in which primarily 3-containing nAChRs function as the postsynaptic receptors [4, 30, 32, 53] . Postsynaptic 9* nAChRs have been detected in rat cochlear hair cells [65] , where they mediate a long-lasting inhibitory response through calciumactivated potassium channels [94] . In contrast, in the mammalian brain only very few potential examples of postsynaptic nAChRs have been documented, for review see [95] . Studies of hippocampal interneurons from rat brain slices and organotypic cultures detected small and infrequent nAChR-mediated currents that were hypothesized to be postsynaptic currents [96] [97] [98] . Better evidence for nAChRmediated synaptic transmission was obtained with neurons in the supraoptic nucleus [99] .
Neuronal nAChRs are most demonstrably involved in presynaptic modulation of synaptic transmission in the CNS. Presynaptic nAChRs have been detected on several cell populations in the brain (e.g. cortex, hippocampus, and cerebellum) where they can modify the excitability of neurons and facilitate release of neurotransmitters such as ACh, dopamine, noradrenaline, GABA, serotonin, and glutamate. Modulation of transmitter release by presynaptic nAChRs was first evidenced in sympathetic ganglion tissue (reviewed by [2, 6, 31] ). Pharmacological evidence supported the occurrence of functional presynaptic receptors, putatively 3 2* and 4 2* nAChRs, that modulate dopamine release from nigrostriatal terminals [100] [101] [102] , but 6* receptors are also implicated in these processes [61] . It is essential to note that 6-containing nAChRs comprise 25-30% of the presynaptic nAChRs in rodents, and, in some tissues, as much as 70% in non-human primates (61, 103, 104] . There is also evidence in the hippocampus and the VTA for presynaptic 7 nAChRs, which regulate glutamate release [105, 106] . Using rat striatal synaptosomes and the putative selective 4 2 receptor agonist UB-165, Sharples et al. demonstrated that 4 2* nAChR modulate dopamine release [107] , and this has been strongly supported by studies with receptor subunit knockout animals [108, 109] . The mechanism for presynaptic modulation of neurotransmitter release by nAChRs is hypothesized to be the regulation of intracellular calcium in the presynaptic bouton [110] ; reviewed by Hogg et al., [6] and by Dajas-Bailador and Wonnacot [45] .
In addition to presynaptic receptors, nAChRs have been found on perisynaptic, extrasynaptic and somatodendritic locations. Perisynaptic 7 nAChRs have been detected in ciliary ganglia [77, 111, 112] , while extrasynaptic 7 receptors have been found transiently during development in tendon [113] and muscle [114] . Additionally, 3-containing nAChRs have an extrasynaptic location in keratonocytes [115, 116] . Taken together, studies of nAChRs in the brain indicate that the potential diversity for multiple kinds of neuronal nAChRs is realized and matched by a complex multitude of potential functions, largely regulating other neurochemical signals. Moreover, different nAChR subtypes can work on opposing elements of a synaptic circuit such as GABAergic and glutamatergic signals in the ventral VTA, part of the mesolimbic dopamine system which has been identified as a key part of the circuitry mediating intravenous nicotine self-administration and release of dopamine in experimental animals [117] [118] [119] [120] [121] [122] . In this tissue, critical functional properties, such as the reversibility of desensitization for the 7 receptors which modulate glutamate release, determine the balance in the system where GABAergic modulations by 4* receptors is transient due to the more profound equilibrium desensitization of that receptor subtype [105] .
Genetics
Variations at the genomic and/or mRNA level further increase the diversity of nAChRs, and the pathological implications of such changes are not completely understood (for review see [123] [124] [125] ). Polymorphisms in genes encoding nAChR subunits have been associated with several neurological disorders, such as schizoprenia [126] , and in autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE); for reviews see [123, 127] . Additionally, nAChR polymorphisms have been implicated in nicotine dependence (reviewed by [123, 124] ); among the candidate genes are CHRNA4, CHRNB2, CHRNA7, and more recently the cluster of genes composed by CHRNA5, CHRNA3, and CHRNB4 located in chromosome 15q24. A link between CHRNA4 gene and nicotine dependence has been demonstrated in several studies [128] [129] [130] . Hutchison and collaborators used an interdisciplinary approach and demonstrated that two singlenucleotide polymorphisms (SNPs) in CHRNA4, rs6122429 and rs2236196, were functional at the biological level and were associated with nicotine dependence. Robust data have revealed an association of polymorphisms in the cluster of genes CHRNA5, CHRNA3, and CHRNB4 not only with nicotine dependence but also with lung cancer. Sacconne et al. found strong association of 5 and 3 nAChR subunits with nicotine dependence, particularly the most compelling biological evidence for a risk factor influencing smoking behavior came from the non-synonymous SNP rs16969968 in CHRNA5 [131] . Additional evidence came from a study by Berrettini and collaborators in which it was demonstrated that a common haplotype in the CHRNA5/CHRNA3 gene cluster predispose to nicotine dependence in three independent populations of European origins [132] . Moreover, the CHRNA5-CHRNA3-CHRNB4 region was identified as an age-dependent susceptibility haplotype in three independent populations of European origins; strong evidence for a link between this locus and nicotine dependence was seen only amongst smokers who began daily smoking early in life (at or before age 16) [133] . Finally, three recent independent genome-wide association studies reported association between the gene cluster containing CHRNA5-CHRNA3-CHRNB4 and lung cancer risk [134] [135] [136] . Whereas Hung et al. and Amos et al. suggested that the association between this gene cluster and lung cancer is less likely to be dependent on smoking behavior, the study by Thorgeirsson et al. pointed to an association between the nAChR gene cluster on chromosome 15q24 and both nicotine dependence and lung cancer risk. Collectively, these studies have provided strong evidence supporting an association of nAChR subunit genomic variations with nicotine dependence and potentially smoking-related diseases.
Activation and Desensitization of nAChR
The most common formalism applied to the study of nAChR activation is based on the assumption that the receptors interconvert among a small number of discreet conformational states. Minimally, these states include; a resting closed state (R), an open state (R*), and a desensitized state (D) [137] . However another factor, defining additional states, is the condition of ligand binding, and for the muscletype nAChR, as well as heteromeric neuronal nAChR, there are two ligand binding sites, so that it is necessary to allow theoretically for each of the three basic states to exist in any one of three levels of occupancy, i. e. with zero, one, or two agonist molecules bound. This is represented in Scheme 1 of Fig. (1) [138] . The conversions between the states in such a model are assumed to be determined by first order rate constants that indicate the probability that the molecule will pass from one state to another as a function of time, and also in the case of the forward binding constants (k 1 , k 2 , k' 1 , k' 2 , k'' 1 , and k'' 2 ) as a function of the concentration of the ligand (A), so that while all of the other rates constants are expressed s -1 , the forward binding constants are s -1 M -1 . A basic principle of these Markov-type models [139] is that a receptor may exist in any one of the states with no "memory" of the state it was in previously, or how long it has been in the current state. At each instant in time it has a certain probability to go from the present state to a connected state or remain in the current state. These probabilities are determined by the rate constants. In the case when two or more paths are connected to the same state, then the ratios of the rates will determine the probability of one conversion versus another. Some conversions are far more likely than others, so it is common for experimentalists to work with simplified models that omit states such as the unliganded open state that are unlikely to exist for very long, if at all.
Functional studies [137, [140] [141] [142] , and more recently structural models based on the acetylcholine binding protein (AChBP) [143] [144] [145] allow us to describe certain features of the three basic states, R, R*, and D. The R, or resting state has relatively low affinity for ACh, presumably because the C-loop, a critical portion of the alpha subunit part of the agonist binding site, is extended slightly away from the underside of the binding pocket. This configuration has been referred to as the "Apo" state [146] . The relatively low agonist affinity of the resting state requires that there be correspondingly high concentrations of agonist present for the receptor to go to the AR and then the A 2 R states. The presence of the agonist in the binding pockets increases the probability that the receptor will convert into the alternative states, activated (R*) or desensitized (D). The probability of going from the resting to activated state is inversely proportional to the opening rates , ', and ''. The rate at which unliganded resting receptors open ( '') is so low [147] that most investigators accept it as zero (although some mutations and allosteric modulators will increase '' [148] ). The opening rate ( ') for resting channels that have bound a single ACh molecule (AR) is much higher than '', but also much less than , the opening rate for doubly bound channels. The closing rate for channels that have bound a single molecule of agonist ( ') is also relatively fast, so that when Fig. (1) . Reaction mechanisms for heteromeric nAChR. Shown are Markov-type models for the activation and desensitization of nAChR with two binding sites for agonists. These models are derived from data obtained in the study of muscle-type nAChR and are likely to be applicable to the heteromeric types of neuronal nAChR, which contain both alpha and beta subunits. Three interconvertable states, R, R*, and D, are shown in both of the schemes, and these states may exist with three levels of agonist occupancy, zero, one, or two molecules of agonist bound. Conversions between the states depend on first order rate constants and the concentration of agonist. Scheme 2 differs from Scheme 1 by hypothesizing a direct connection between the activated (R*) and desensitized states (D).
low concentrations of agonist are present, channel openings are observed, but they are very brief. With progressively increasing agonist concentrations, briefer events are seen until channels are more likely to be in the A 2 R state than the AR state, and then periods of activation associated with the A 2 R* predominate [140, 141] . Not only is larger than ', but is much slower than ', so that at least for muscle type receptors, doubly liganded channels produce relatively long (1-5 millisecond) periods of activation. We know that the activation process changes the agonist binding site, producing a much tighter (i. e. high affinity) binding of ACh. This has been demonstrated with single channel studies which indicated that once the channel is active, agonist stays bound, in general, at least as long as the channel is open. As a consequence, open channels often convert back to the A 2 R state, from which they may open again. This process has been studied in detail through the analysis of bursts of channel openings [149] [150] [151] . The change in agonist off rate (k' -2 << k -2 ) concomitant to gating (i. e. conversion from the resting to the active state) is most likely associated with reconfiguration of the C-loop and other elements of the binding site to an alternative low energy conformation around the agonist molecule. The energy from this binding then catalyzes a cascade of conformational changes that ultimately results in the opening of the ion pore.
It has been proposed that in the muscle-type nAChR, a tyrosine (Y188) moves down as part of the C-loop and disrupts a salt bridge between aspartate and lysine residues in the floor of the binding pocket [152] . This then permits other movements within the extracellular domain, including movement of the cys-loop. The cys-loop is believed to make critical contacts with a small loop of extracellular sequence between transmembrane domains 2 and 3 (the ECL, extra cellular loop), such that during the conversion from R to R*, TM2, the pore lining domain, is either rotated or pushed back in order to form the open channel for ion conduction [153] . This gating process may involve the isomerization of a proline residue within the ECL from the trans to cis configuration [154] . While data to support the importance of the Y-K-D triad of amino acids for the ACh initiation of gating in muscle nAChR, these same amino acids appear to play important but different roles in neuronal AChR [155] . For example, while the mutation of tyrosine 188 to phenylalanine decreases the potency of ACh for activation of 7 nAChR, as it does for muscle type receptors, it does not decrease ACh potency for 4 2 receptors. Interestingly, in the neuronal 4 2, tyrosine 188 seems to play a role in preventing the receptors from being activated by compounds such as 4OH-GTS-21, which normally activates 7 receptors 40-60% as well as ACh but produces 20-fold less activation of 4 2 (2% the efficacy of ACh). When the tyrosine 188 of 4 is mutated to phenylalanine, the efficacy of 4OH-GTS-21 increases by more than a factor of 200, so that it becomes 4-5 fold more efficacious than ACh. Interestingly, in 7 the same Y188F mutation has no major effect on either the efficacy or potency of 4OH-GTS-21, although, as noted above, ACh potency is decreased about 200-fold. These observations suggest that although movement of the C-loop is a critical aspect for initiating the conversion of receptors from the R to the R* state, the precise way in which the necessary energy is generated will depend on the specific agonist and receptor subtype.
While electrophysiological approaches, and single channel recordings in particular have provided great insights into the process of channel activation (conversions between the A and R* states), these approaches are largely blind to the desensitized state, since the R and D states appear the same to an electrode. Structural approaches confirm that heteromeric receptors in the D state bind agonist with high affinity [156] . In fact, it should be generally assumed that virtually all structural models of an agonist bound to nAChR are models of the agonist binding site of a desensitized receptor. However, it is an open question to what degree the changes in the agonist binding site that occur upon activation are the same changes in agonist binding site that occur in the transition from the resting to desensitized states. Two possibilities should be considered. One possibility, represented in Scheme 1 (Fig. 1) , is that once an agonist molecule falls into the rather loose-fitting site of a resting receptor, the presence of the agonist molecule can promote conversion to either one of two different high affinity states. Conversion to the R* high affinity state uses some of the binding energy to open the channel. Conversion to the alternative high affinity state, D, does not involve gating the channel. In this scenario it is likely that there might be significant difference in the binding sites of receptors of R* and D states.
Another possibility is that conversion to the D state is most likely to occur from the R* state rather than the R state. In this scenario, the high affinity configuration of the agonist binding site, that is created when the channel is activated, would be retained but some further conformational change would return the channel to a non-conducting state. It has been suggested that there might exist a "desensitization gate", a closed channel configuration structurally distinct from that of the resting closed state [157] . This would be analogous to the inactivation gate of voltage dependent channels [158] . However, there is very little direct evidence for such a desensitization gate. It has been proposed that the 7L247T mutant is able to conduct current under what would otherwise be desensitizing conditions [159] suggesting that the L247 residue might in fact contribute to a desensitization gate in the wild type 7. However, the 7L247T also may conduct current in resting or antagonized conditions [160, 161] and so the L247 might also contribute to the gate of the resting channel. If there is no desensitization gate per se, then perhaps desensitization is the process by which the pore forming domain basically returns to its resting conformation while the ligand binding domains retains in its high affinity form (Fig. 2) . It may be that contacts between the cys-loop and the ECL catalyze the isomerization of the proline within the ECL that gates the channel, but that as a first order process, on the time scale of the apparent desensitization rates, the proline converts back to the trans form, regenerating the non-conducting state.
By carefully controlling the conditions for rapid agonist application to the receptor from the Torpedo ray electric organ, which is an analogue of a muscle nAChR, Nigel Unwin and colleagues have been able to obtain images of that receptor in both the open and closed states [162] . However, although one might imagine that it would be possible to compare images obtained in the absence of agonist to ones obtained after the prolonged application of agonist and thereby compare the channel domains of receptors in the R and D states, images of putative desensitized channel domains are difficult to obtain at resolutions adequate for comparison to receptors in the resting state (N. Unwin, personal communication). The reason for this is uncertain, but Dr. Unwin speculates that the activation/desensitization processes might destabilize the crystals, or perhaps the crystals become conformationally heterogeneous, containing a mixture of differently desensitized states. It should be noted that although the models in Fig. (1) may appear complex, they are minimal and almost certainly over-simplified, especially in regard to desensitization. Consistent with Dr. Unwin's statement, several lines of evidence, including direct observations of single channel currents, indicate that conversion between activatable and desensitized states can occur on multiple time scales [163, [164] [165] [166] [167] . So called, "levels of deep desensitization" or "long-term inactivation" have been reported, and conversion to these states may involve protein phosphorylation [168, 169] or other processes [170] not accounted for in the "simple" activation schemes shown in Fig. (1) .
It is appropriate to think of nAChRs as "allosteric" proteins. The presence of ligands such as ACh, and other drugs which bind to alternative sites on the protein influence the conformational equilibrium between the various states on both short and long time scales [171] [172] [173] [174] . For example, consider that a population of receptors, described by the models represented in Schemes 1 and 2, would be found in the various states under equilibrium conditions with a fixed concentration of agonist. In the absence of agonist, all receptors would be in the left most column of states, and since the D and R* states are unstable in the absence of agonist, nearly all the receptors would be in the R state. This ratio of the number of receptors in the D state to those in the R state in the absence of agonist has been referred to as the "allosteric ratio" [137] . It is very low indeed under normal conditions but it can be perturbed by disruption of the membrane or the presence of ligands which bind to the receptors at sites other than the ACh binding site. At the opposite extreme, when receptors have been allowed to equilibrate with a concentration of agonist sufficiently high to saturate the low affinity binding sites of the R state, all of the receptors will be in the right-most column of states. The distribution of receptors among these three states will depend on the relative stability of the three states, that is the ratio between the sum of the rates for entering the particular state relative to the sum of the rates for leaving that state. With the assumption of saturating conditions of agonist, all transitions involving agonist dissociation can be ignored. Typically, although channel opening rates ( ) are greater than desensitization rates (d + ), resensitization rates (d -) are much slower than channel closing rates. Therefore, with equilibration under conditions of high concentrations of agonist the large majority of receptors will be in the D state. Therefore the D state can be considered as "absorbing", although channels will sporadically escape from desensitization and generate a burst of opening Fig. (2) . Key structural elements of single AChR subunits. Shown are schematic representations of single alpha-type subunits and a hypothetical mechanism for the interconversion among the R, R*, and D states, as catalyzed by the presence of acetylcholine in the agonist binding site. Four key domains are indicated in the leftmost cartoon (R): the C-loop of the agonist binding site, the disulfide bonded cys-loop, the TM2 pore-lining domain, and the extracellular loop (ECL). These are believed to be critical for the coupling agonist binding to gating. The leftmost cartoon also indicates the location of the pore relative to another subunit (in gray) in a complete pentamer. For clarity, the other subunit is omitted in the other cartoons. In the AR state ACh is bound with relatively low affinity and the C-loop is in the Apo position. The conversion from the AR to AR* state is associated with movement of the four critical domains within the alpha subunit. The C-loop lowers to a position which creates the high affinity configuration of the agonist binding site. The cys-loop interacts with the ECL, which results in movement of the TM2 opening the ion channel. The right-most cartoon illustrates a hypothetical configuration of these four domains in the D state, such that the agonist binding site remains in the high affinity form, but the channel domain has returned to the configuration of the R state.
before returning to the D state. Between the two extremes of agonist concentrations, the fact that the D state has higher agonist affinity than the R state means that at steady state in the constant presence of agonist there will still be a greater tendency for those channels that convert to the D state to retain bound agonist than for receptors that remain in the R state. Therefore over time receptors will still accumulate in the D state compared to the R state. This accounts for the phenomenon referred to as "pre-desensitization" [175] in which prolonged exposure to a relatively low concentration of agonist, too low to effectively bind to receptors in the R state, can deplete the population of readily activatable receptors in the R state. In this case, when a brief pulse of high concentration of agonist is applied, the number of channels that will open is fewer than if the receptors had not been previously exposed to the low concentration of agonist.
However, homomeric 7 receptors, which lack the specialization of the non-alpha subunits at the agonist binding sites, do not show the same high affinity conversion of their agonist binding sites as their muscle and other neuronal receptors counterparts [176] . It has been estimated that the agonist binding site of desensitized 7 receptors has only about 10-fold higher affinity for agonist than does the R state of 7 receptors, while for heteromeric receptors this difference is 2-3 orders of magnitude larger. Because desensitized 7 receptors do not retain agonist with as high affinity nAChRs, the desensitized state of these receptors is not absorbing in the same sense as with the heteromeric receptor. However, 7 receptors have five rather than just two agonist binding sites, and it has been proposed that once 7 receptors have opened and desensitized, they are likely to remain desensitized as long as any of those binding sites are occupied. While high concentrations of agonist are very effective at driving 7 receptors into desensitized states and keeping them there, low concentrations of agonist, sufficient to bind only one or two of the five agonist binding sites can produce activation [177] . Desensitization still occurs under these conditions, but because binding and desensitization are both readily reversible, equilibrium can be maintained with low levels of channel activation for prolonged periods of time at low agonist concentration. This may be relevant for the effects of nicotine on these receptors as well as for the endogenous agonists ACh and choline [178] .
Agonists, Partial Agonists, Allosteric Modulators and Antagonists
In the search for candidate drugs to treat nicotine addiction and to understand the functional properties of the drug targets, we have to take into consideration the specific nAChR in the brain responsible for addiction and dependence. Five classes of drugs which should be considered are: agonists, partial agonists, allosteric modulators, noncompetitive antagonists, and competitive antagonists.
ACh can be considered as our reference compound for the comparison of other compounds that might activate the nAChR by binding to the same site on the receptor as does ACh. Any compound which, when applied in the same manner that ACh is applied, produces the same maximal response as ACh is, by definition, a "full" agonist. Specific drugs might be either more potent or less potent than ACh, depending on how much of the drug is required to evoke a maximal response. In the context of the activation mechanisms in Fig. (1) , an experimental full agonist X would just substitute for A, producing similar results when applied at a concentration adjusted for any difference in potency. However, in a therapeutic context it must be considered that the presentation of an experimental agonist will not mimic the presentation of the natural activator ACh. For example, levels of the experimental drug in the hippocampus will not oscillate in the way that ACh levels will oscillate in response to rhythmic input of the septal cholinergic pathway [179] [180] [181] . Rather, the experimental drug will effectively be present at steady levels which may produce some equilibrium activation at certain concentrations, but at other concentrations the steady state presence of the experimental drug may be predominately desensitizing and thereby blunt the effects of the intrinsic cholinergic signals.
A partial agonist is a drug which, when substituted for A in the activation mechanism, consistently fails to produce the same maximal activation as produced by ACh when applied in the same manner, with appropriate compensation for differences in potency. We can look at the models and see several ways in which one drug might fail to produce as much activation as another; all we need to assume is that the rate constants associated with one or more of the ligand bound states depend equally on the nature of the ligand as on the receptor. This principle has been well established by many single channel experiments [141, 182] . For example, the channel opening rate might be lower when a partial agonist is bound than when a full agonist is bound, or alternatively the closing rate might be faster. Likewise, desensitization rates might be faster for a partial agonist than for a full agonist, or re-sensitization rates slower. In a therapeutic context, the effects of a partial agonist will be similar to those of a full agonist except that equilibrium activation would likely be lower and the blunting effects on other stimuli (including systemically administered nicotine, as well as endogenous ACh) likely to be greater [183] . "Allosteric modulators" is a term applied to molecules which bind to the receptor at sites other than the primary agonist binding sites, and when bound alter the reaction rates for the various conformational transitions. If an allosteric ligand were added to our model, we would need to add a second surface for all of the multiple states when the allosteric ligand is also bound. If the net effect of the allosteric ligand is to alter the rates when bound such that the net amount of time in the R* states is increased, then the ligand is considered a positive allosteric modulator (PAM). Several types of PAMs have been discovered for increasing the activation of 7 nAChR [148] . If a drug intended to treat nicotine addiction had an undesirable side effect because of decreased 7 function, then the use of an 7 PAM might be considered.
If the net effect of the binding of an allosteric modulator is to decrease time in the R* state, then the drug would be considered a negative allosteric modulator. Such a drug could also be classified as a noncompetitive antagonist. Another class of noncompetitive antagonists is comprised of drugs which bind specifically to activated receptors, usually by binding to the open channel itself. This form of inhibition is usually use-dependent and so produces the greatest inhibition when the stimulation of the receptor is greatest [184] .
This could conceivably have a therapeutic utility for treating nicotine addiction since such a drug might most effectively inhibit those channels most readily activated by nicotine. Competitive antagonists are drugs which bind to the ACh binding site but produce no activation. Some competitive antagonists have very slow off rates and so produce profound inhibition. For example, -bungarotoxin binds to 7 receptors with such high affinity that it can be used to label 7 receptors in brain slices, while agonists cannot be used for that purpose [185] . As is the case for the effects of curare on the muscle-type nAChR, it is sometimes impossible to distinguish between a competitive antagonist and a partial agonist with very low efficacy [186] .
The question of which sort of drug would be useful to treat nicotine addiction is compounded by our need to consider the issues related to the multiplicity of nAChR subtypes and the fact that drugs may not only show selectivity for one nAChR subtype over another but may also have different mechanisms of action on different receptor subtypes. An example of a drug whose effects are fraught with such complications is nicotine. Nicotine is a full agonist for some receptor subtypes and a partial agonist for others. Nicotine has also been reported to act as a noncompetitive antagonist, and to work not only on cell surface receptors but also to work intracellularly as molecular chaperone modulating the expression of specific receptor subtypes. Therefore, the challenges presented for developing treatments for nicotine dependence will begin with describing the multiple effects of nicotine on the various nAChR subtypes, and sorting out which of those effects underlie dependence and addiction and which do not. Addiction therapies targeting nAChR will have to be focused and most importantly, not interfere with normal cholinergic function in the brain. Moreover, as there is also an increasing perception that the activation of specific neuronal nAChR may be therapeutic indications for treatment of neuropathologies such as schizophrenia and Alzheimer's disease, the development of truly selective agents, whether they are antagonists, agonists, or partial agonists will be of great importance. In the remainder of this review, we will discuss the significance roles played by neuronal nAChR in the context of addiction and the rationales for receptor-directed treatments.
NICOTINIC RECEPTOR AS TARGET FOR PHARMACOTHERAPY OF NICOTINE ADDICTION

Evidence from Behavioral Research
Nicotine Addiction and Existing Pharmacotherapeutics
Nicotine addiction is believed to be the key component in sustaining the use of tobacco products, although other elements of tobacco and tobacco smoke such as monoamine oxidase and acetaldehyde do influence the behavior. Given that nicotine is much less harmful than the other constituents of tobacco and tobacco smoke, if harmful at all, the development of pharmacotherapeutics based on nAChRs would seem to be an obvious strategy. In fact, the first line medications on the market today to treat nicotine addiction are all nicotinic or have a nicotinic component. These include various nicotine-replacement therapies (NRTs, formulations as polacrilex gum, nicotine patch, inhaler, microtab, nasal spray, lozenge), the antidepressant bupropion which is a dopamine and norepinephrine re-uptake inhibitor with additional activity as a nicotinic antagonist [187] , and varenicline, a partial agonist at 4 2-containing nAChRs but active at other nAChRs as well [188] . However, varenicline is the only one that has been produced by the drug discovery to development approach typically used by the pharmaceutical industry [189, 190] . These medications improve smoking cessation outcomes, but the long-term quit rate is still low [191] and there have been reports of serious adverse effects with varenicline [192, 193] . Additional medication development programs for the treatment of nicotine addiction are needed.
Addiction to any drug develops after repeated voluntary exposure in psychoactive amounts, typically beginning with occasional use, progressing to more regular patterns, and culminating in use which the user cannot easily stop. The components of addiction are recognizable as the selfadministration of the drug, withdrawal symptoms when use is stopped, and relapse to drug use during periods of abstinence. Tolerance can also be observed. Substantial efforts in neuroscience have resulted in advances in our understanding of the mechanisms of addiction and theories have been proposed to integrate these biological and psychological processes in a coherent framework (see review in [194] ). From a simple concept of reinforcement due to overt subjectivelypositive effects of a drug, more complex theories have proposed other concepts, such as the sensitization of the response to environmental stimuli associated with drug exposure which become progressively more salient and activate appetitive systems that mediate a 'drug wanting' subjective state [195] , or a theory in which the motivation for use becomes maintained by attempts to overcome a dys-regulation of reward systems and activation of stress responses [196] . Additional components, such as cognitive, arousal, attentional and memory processes, likely also contribute significantly to the phenomenon of addiction.
Behavioral Models in Nicotine Addiction Research
Given the diversity of nAChR-directed molecular entities that could be synthesized or extracted as natural products, an obvious question is how one would proceed to test these for their potential efficacy in addictive disorders? In fact, an impressive set of sophisticated behavioral pharmacological models has been developed to study the mechanisms of addiction. While these models have been exceptionally useful in discovering brain nuclei, circuitry, and mechanisms of reward, reinforcement, withdrawal and relapse, they can equally be employed in drug discovery. A recent review provides a detailed account of these animal behavioral pharmacological models, as well as models for preclinical studies in human subjects, accompanied by examples of their application [197] , hence coverage here will be brief.
Behavioral pharmacological models in animals include those with which to study the positive reinforcing and rewarding effects of nicotine as well as ones that can be used to examine negative effects. In the case of the former, voluntary drug-taking behavior can be studied with an approach in which animals are required to perform a task (such as pressing a lever or operating a manipulandum) to receive the drug. For nicotine, these studies are typically done with the drug administered intravenously through a chronic in-dwelling catheter. Research with primates and rodents has established that animals will respond for nicotine at various levels of task load or complexity.
Positive effects of a drug can also be measured with intracranial self-stimulation (ICSS), which purports to measure rewarding effects. Conditioned rewarding effects can be measured with a paradigm in which animals register preference for a drug (or aversion to it) by the time spent in a distinct environment that has been paired with the drug compared to another environment that has been paired with vehicle. Stimuli paired with drugs can acquire reinforcing properties, and maintain behavior, delay extinction, and reinstate extinguished behavior.
Models are also available to study the negative effects of chronic nicotine exposure as manifest by withdrawal and relapse. Paradigms include measurement of the threshold for ICSS which is increased in withdrawal and physical signs similar to a less-intense version of those observed in opiate withdrawal. Relapse can also be modeled in animal studies. To accomplish this, the behavior of animals trained to selfadminister a drug is extinguished; subsequent exposure to drug-paired cues or non-contingent delivery of the drug can reinstate responding on the experimental manipulandum in the absence of contingent drug delivery. Reinstatement of nicotine-seeking behavior occurs reliably with cue exposure but is less reliable following non-contingent re-exposure to the drug. Information gathered with these models can be augmented by measures of the discriminative stimulus characteristics of a drug, and its effects on other CNS functions including arousal, attention and sensory registration.
Application Models to the Drug Discovery Process for Nicotine Addiction
It is straightforward to apply the behavioral models described above to drug discovery for nicotinic ligands. In addition, findings from studies with these models, some of which are complex but do have face-validity, can be augmented with data from assays using simpler behavioral and physiological read-outs. For example, nicotinic ligands alter physiological functions such as temperature regulation and analgesia; hence novel ligands can be assessed for activity with simple biological measurements. In addition, simple behavioral assays, such as motor activity in a novel environment or in one to which the subjects have been habituated, or drug sensitization models, in which activity is enhanced after repeated exposure, can also be used. Furthermore, simple measures can be used to assess undesirable characteristics of a novel ligand, such as anorexic or cataleptic effects. Therefore in ligand discovery for nicotinic compounds there is the opportunity to evaluate chemical entities across a large assembly of potential 'screening' measures of increasing complexity, a fact which should tilt the balance in favor of early decisions regarding a given entity and yield, at the least, novel research tools with defined profiles of actions. Translational research to this extent can be achieved by researchers in academic settings, and is happening to a limited extent for nAChR ligands (see example [198] [199] [200] [201] [202] [203] ).
Although the focus in this paper is on animal models, it is worth noting that in at least some cases very similar behavioral models exist for use with human subjects, such as selfadministration paradigms, measurement of subjective effects which can be compared with drug discrimination studies, attentional tasks and sensory gating [247] . For the pharmaceutical industry, therefore, there would appear to be a relatively straightforward translation possible at least to preclinical studies in human subjects. However, there are impediments to the latter, one of the most vexing being that neither animal behavioral pharmacological models nor human laboratory paradigms are known to be predictive for medication development.
In the case of animal models, this is may not be surprising. Although the models have been designed to isolate particular elements of addiction for research, with a few exceptions, they typically do not aim to replicate the human situation. For example, the self-administration model does not usually aim to use patterns of nicotine intake that mimic smoking behavior in humans. Rather they use short-duration daily access to the drug, because of the nature of the question of interest, for instance, the identity or function of a particular part of the circuitry contributing to the positive reinforcing effects of nicotine in brain. This is important information in elaborating CNS mechanisms, but it may or may not be an appropriate model with which to test potential pharmacotherapeutics in the early preclinical stages. The reason it may not be appropriate is, of course, the possibility that CNS changes, which accompany chronic drug use in the longterm tobacco smoker, may not be captured by a model in which drug exposure has been limited. Models which aim to replicate the human situation more closely are being used in some cases; for example in self-administration, more substantial nicotine intake can be obtained, sufficient to yield withdrawal symptoms upon cessation [204] . It remains to be seen if such approaches provide better behavioral tools for translational research.
As noted, the sole example to-date of drug discovery for nicotine addiction is varenicline, a partial agonist at 4 2 nAChRs at clinical doses. Given this limited experience, what can we say about animal models? First, animal behavioral evidence influenced the choice to target 2-containing receptors in the development of a molecule like varenicline because behavioral research had shown this population to be relevant. For example, nicotine self-administration [205, 206] , nicotine potentiation of ICSS [207] , drug discrimination [208] [209] [210] and locomotor activity [205, 210] are altered by the nicotinic antagonist dihydro-beta-erythroidine (DH E), which acts at 2 containing receptors, whereas the 7 antagonist methyllycaconitine (MLA) generally has no effect on behaviors of this kind (but see [211] ).
In preclinical studies, varenicline performed in selfadministration as one would expect from a partial agonist at 4 2-containing receptors, that is, it antagonized nicotinemaintained responding but did not maintain responding to the same extent as nicotine in substitution tests [212] . In drug discrimination tests, however, varenicline has been reported to generalize either fully [212] or only partially to the nicotine cue [213, 214] . This variability and the somewhat surprising full generalization may be due to methodological differences; obviously application of these models would need to be done consistently in a series of studies on a range of compounds, and across comparisons. Smith et al. [214] used the drug discrimination assay to demonstrate that generalization to the nicotine cue requires high affinity and ac-tivity at 2-containing but not 4-or 7-containing nAChRs.
Although NRTs and bupropion did not result from typical the drug discovery approach, examination of their effects in animal behavioral pharmacological models shows that the models are responsive. For example, effects of NRT can be mimicked by acute or chronic nicotine administration in behavioral pharmacological tests. Nicotine self-administration is decreased after either acute administration of nicotine [215] or after chronic infusion in short sessions [216] or 23-hour ones [217] . Nicotine administered to animals in withdrawal reduces the somatic signs [218] and can attenuate drug discrimination [219] .
Bupropion is metabolized differently in rats than in humans and mice; rats do not produce the S,S-hydroxy metabolite which appears to be the clinically active entity, suggesting that behavioral pharmacological studies in rats should be done by administering the metabolite. Nonetheless, studies which have examined bupropion itself in rat-based models do report effects. These include dose-related effects on nicotine self-administration, with increases at moderate bupropion doses and decreases at high doses, and appear to be dependent on the operant schedule used in that bupropion was reported to be without effect on a schedule in which the response requirements escalated during the session [220] [221] [222] [223] . Bupropion reduced the somatic signs of nicotine withdrawal and the increase in threshold for brain reward stimulation that occurs in withdrawal [224, 225] . However, in drug discrimination studies, bupropion has been reported to have mixed effects on substitution in several studies, including full, partial or no substitution [223, [226] [227] [228] [229] , and to be without antagonist effects on the nicotine cue. Thus, although behavioral models do exist to support the development of nAChR pharmacotherapeutics, the variability in the few studies that have been done with existing medications shows that caution is required in their application, likely including such obvious factors such as consistent training and dosing conditions but also perhaps unknown factors as well.
Nonetheless, these studies do provide at least a first-order level of confidence that the animal behavioral models available are responsive to effects of medications for nicotine addiction. Indeed, in the ongoing development of a nicotine vaccine, preclinical behavioral studies have been used to show that reduction of nicotine levels by antibody binding is sufficient to attenuate nicotine self administration [204, 230] and the nicotine-primed reinstatement of extinguished responding [231] . Immunization was also associated with a reduction in the reward-facilitating effects of nicotine as measured in ICSS, and attenuated withdrawal symptoms [232] . Antibody levels appear to bear a "dose-response" relationship to behavioral effects because combined vaccination and passive immunization, which produced higher serum nicotine antibody levels, was associated with greater attenuation of locomotor sensitization than either vaccination or passive immunization alone [233] .
Confidence that behavioral models of addiction would be responsive to selective nAChR ligands is increased by studies with mutant mice. Although establishing certain behavioral models has proved to be difficult for some paradigms in the mouse, especially those requiring operant responses, generally the same range of behavioral dimensions (reward, withdrawal, etc.) can be measured as in the rat, the latter being the more widely used species for behavioral pharmacological research. Studies with knock-out (KO) and gain-offunction knock-in (KI) mutant mice in these models have been instructive. An early example is the demonstration that nicotine self-administration was reduced in 2 KO mice [108] . Advances have also been made using alternative measures to tasks requiring an operant response, such as preference approaches to examine conditioned reward. As a result, we have substantial information about the role of 2-containing receptors in behaviors relevant to nicotine addiction, including their role in conditioned reinforcement [234] and reward [235] , in the affective signs of withdrawal [236] , in dopamine-dependent locomotor sensitization [237] and in the discriminative stimulus and conditioned aversive effects of nicotine [238] , as well as in behaviors that are very likely to play a role in contextual learning [239] . In addition, studies with null mutant mice have shed light on subtypes that do not appear to play a direct role in certain addiction-related phenomena, but may be linked to others; in specific, 7 seems not to be involved in the acquisition of a nicotine discriminative cue nor the depressant effects of the drug [240, 241] but has recently been implicated in the somatic signs of withdrawal [236, 242] . The 4 subunit has also been implicated in the somatic signs of withdrawal [243] . Studies with mutant mice with hypersensitive and KO 4 nAChRs have shown that this subtype is involved in conditioned reward and locomotor sensitization [244, 245] . In addition, studies with mice bearing gain-of-function 6* nAChRs show that receptors with this subunit may be valuable targets for development because they influence dopamine release [344] . There is clear utility of mutant mice in development of nicotinic pharmacotherapies [246] , particularly when these animals are employed in behavioral testing. Certainly behavioral findings with these genetic models show that nicotinic effects can be segregated at least partially in terms of receptor subtype, and suggest that target choices amongst the subtypes may be narrowed. Of course it remains an open question whether such potential improved selectivity in profiling would benefit the development of pharmacotherapeutics for nicotine addiction.
In conclusion, although there appears to have been limited effort expended in the pharmaceutical industry for nicotine addiction, the behavioral pharmacological tools to support this activity do exist. These tools can differentiate between nAChR subtypes, and are responsive to medicationrelated manipulations. However, several notes of caution need to be made. The first has already been noted, namely, that preclinical models have not been validated for their predictive validity in nicotine addiction. This statement applies to both human laboratory models which show limited-to-no effectiveness with medications like NRTs and bupropion, as well as animal paradigms which to-date have not been found to have distinct response profiles when the treatment is, or mimics, a medication and, in addition, may show limited responsiveness. This issue has been discussed in detail elsewhere [179] ; one straightforward way to begin to address this would be to screen approved medications for treatment of tobacco addiction, as well as medications approved for other indications where the presumptive target is of relevance, across the range of animal and human laboratory paradigms. A second is that each of these behavioral models is responsive to a variety of manipulations. This includes the few medication-related manipulations described herein, as well as systemic treatment with a range of other compounds, and central manipulation with microinfusions and neurotoxin lesions that have been examined in behavioral neuroscience research. This fact underscores that an effect in a given model is not sufficient to predict efficacy as a pharmacotherapy. In addition, no pattern or 'fingerprint' has emerged with the existing medications which would have predicted their efficacy.
Another salient point is to recognize that non-human species may not possess the "behavioral readout" necessary to support the development of pharmacotherapeutics relevant to a complex biobehavioral phenomenon like addiction. It may be that circuitry, which is well conserved between species, is more relevant than behavior in cross-species comparisons [247] . In addition, clinical neuroscience studies that are now possible with imaging may allow relevant cross-species comparisons. For example, the recent observation suggesting increased availability of 2-containing receptors in early abstinence [248] could be explored in animal behavioral pharmacological studies for animal-to-human validation.
Evidence from Neurochemical and Other Research
The mesolimbic dopamine (DA) system, which originates in the VTA and projects to the nucleus accumbens (NAcc), is a critical component of the reward circuitry activated by drugs of abuse, including nicotine [117, 249, [250] [251] [252] [253] [254] . Nicotine exerts its effects by stimulating nAChR subtypes in various regions of the mammalian brain, including NAcc and VTA of the mesolimbic dopamine system [69, 255, 256] . Nicotinic receptor subtypes expressed in the mesolimbic DA system may play a role in mediating the rewarding effect of nicotine [122, 211] . Electrophysiological studies have shown that nicotine, by acting at nAChRs, directly stimulates dopamine cells [257] . Accumulated evidence indicates that heteromeric nAChRs containing the 2 subunit are predominant in the striatum and NAcc, and are expressed with either the -4 or -6 subunit [258] [259] [260] . Furthermore, genetic studies in mice implicate 2-containing nAChRs in nicotine-evoked DA release [108, [261] [262] [263] [264] . Generally, it is thought that nicotine, at a concentration relevant to smoking, activates DA neurons by stimulating predominantly heteromeric 2-containing nAChRs in the VTA [105, 108, 244] .
Using genetic studies, it has been demonstrated that at least six different nAChR subtypes mediate nicotine-evoked DA release from mouse striatum, including -conotoxin-MII ( -CtxMII)-sensitive nAChRs (i.e., 6 2 3*, 4 6 2 3* and possibly a small amount of 6 2* or 4 6 2* subtypes) and -CtxMII-resistant nAChRs (i.e., 4 2* and 4 5 2* subtypes), whereas deletion of 4 and 7 subunits had no effect [61, 265] . In addition, nAChRs containing 6 and 3 subunits have been implicated in nicotine-evoked DA release [57, 59, 266] . As noted, substantia nigra and VTA neurons express high levels of both 6 and 3 mRNAs [60, [266] [267] [268] , consistent with the involvement of subtypes containing these subunits in mediating nicotine-evoked DA release. Overall, the results summarized here support the notion that 6-containing nAChRs are also important substrates for the actions of nicotine in the brain. Furthermore, the 4 6 2 3* nAChR subtype constitutes about 50% of 6-containing nAChRs on DA terminals of wild type mice and is the most sensitive to activation by nicotine, which strongly implicates the 4 6 2 3* subtype in nicotineevoked DA release and nicotine mediated reward.
Although in general, data indicate that 7-containing receptors are not as important for the addicting effects of nicotine as are the various heteromeric 4* and 6* receptors, nonetheless they have been shown to play significant roles in the circuits of the reward systems in the brain. Specifically, 7 receptors are located on glutamatergic presynaptic terminals in the VTA and substantia nigra, and as such may also play a role in mediating nicotine-evoked DA release and reward [256, 269] . Nicotine therefore can indirectly stimulate VTA DA neurons through 7 nAChRs located on glutamatergic presynaptic terminals leading to glutamate release [256, 269, 270] . Thus, differential effects of nicotine are determined by the location and functional status of nAChR subtypes in the mesolimbic system [271] . The ratio of the expressed subunits and subtypes in individual DA neurons, and the pharmacological history of the organism are also important to neuronal function and may play an important role in the response to nicotine. Moreover, as noted, strong evidence suggests that exposure to nicotine can influence nAChR subtype stoichiometry, function, and maturity in recombinant receptor systems [12, 14, 272] .
In vivo microdialysis studies demonstrated that nicotine enhances DA release in NAcc following local and systemic administration [119] [120] [121] [273] [274] [275] [276] [277] [278] [279] [280] [281] [282] [283] and this is believed to be one of the primary mechanisms involved in the reinforcing effect of nicotine [249, 252, 254] . The nicotine-induced enhancement of extracellular DA in NAcc is inhibited by systemic [122, [273] [274] [275] [276] or local VTA perfusion of nonselective nAChR antagonists, such as mecamylamine and novel bispicolinium compounds [119] [120] [121] [280] [281] [282] . In addition, local NAcc perfusion of mecamylamine or the 7 antagonist MLA has been shown to modulate systemic or local nicotine-induced DA release in the NAcc [277, 280] . On the other hand, repeated nicotine (0.4 mg/kg, sc) administration for 5 days sensitizes mesolimbic DA release to a subsequent challenge dose of nicotine [120, 273, 283] . Pretreatment with mecamylamine attenuates nicotine-induced mesolimbic DA release in sensitized animals, further implicating a role for nAChRs in the psychostimulant effects of nicotine [121, 275, 277] . Additionally, -CtxMII, which binds 6-containing nAChRs with high affinity and binds 3-containing nAChRs with lower affinity [284, 285] , was found to partially inhibit nicotine-evoked DA release from striatal synaptosomes, supporting the involvement of 6-and/or 3-containing nAChRs [286, 287] .
Targeting nAChR subtypes in brain reward circuitry will provide potential pharmacotherapies for nicotine addiction. For example, varenicline has been shown to be a partial agonist at 4 2 nAChRs, and although a full agonist at 7, this action may not be realized at clinically used doses [188, 189] . In contrast, bupropion inhibits multiple nAChR subtypes, and also inhibits neurotransmitter transporters resulting in accumulation of extracellular DA in the NAcc among other effects [288] [289] [290] [291] .
In conclusion, neurochemical, genetic and electrophysiological studies clearly demonstrate that brain nAChRs in the mesolimbic DA system are potential targets for nicotineinduced changes in brain neurochemical markers associated with nicotine mediated reward and addictive behavior. Thus nAChRs are demonstrably valid targets for potential pharmacotherapy for tobacco and smoking addiction. Further discovery and additional pharmacological characterization of selective novel medicinal agents targeting brain nAChR subtype(s) specifically involved in brain reward neurocircuitry may offer better therapeutic outcome over existing pharmacotherapy.
NICOTINE RECEPTORS AND OTHER FORMS OF DRUG ADDICTION
Alcoholism
Alcoholism and nicotine addiction often co-occur in humans, a fact well documented in the literature [292] [293] [294] . Furthermore, a genetic co-relation appears to exist between these two disorders [295, 296] . It is now well established that both nicotine and alcohol can either directly or indirectly activate the brain reward system through neuronal nAChRs [270, 297, 298] . Several studies have indicated that mecamylamine, a nonselective nAChR antagonist, reduced alcohol drinking in rodent models [299] [300] [301] . Additionally, mecamylamine has been found to prevent the stimulant or euphoric subjective effects of alcohol and reduce the desire to consume more alcohol in humans [302] [303] [304] . Further, mecamylamine was shown to reduce alcohol-induced locomotor stimulation in mice [305] [306] [307] . Varenicline, the 4 2 nAChR partial agonist, has been found to decrease alcohol consumption and alcohol-seeking behavior in an animal model [308] . In addition to behavioral assays, neurochemical studies suggest that mecamylamine attenuated ethanolinduced extracellular DA levels in the mesolimbic system of rats and mice [306, [309] [310] [311] [312] [313] . Furthermore, pretreatment or intra-VTA perfusion of mecamylamine reduces voluntary alcohol-intake and preference in alcohol preferring rats [310, 314] . Interestingly, pretreatment with DH E, an antagonist at 4 2 containing nAChR subtypes, failed to affect alcohol self-administration in limited access drinking paradigm [301] or alcohol-induced locomotor stimulatory effect or alcoholinduced increase mesolimbic DA release [306] . This is surprising given the fact that mice lacking the 2 subunits do not self-administer nicotine [108] . Thus, neurochemical and behavioral studies suggest 4 2 nAChR subtypes are not equally important for alcohol induced behavioral and neurochemical effects. Similarly, MLA failed to alter both stimulatory effects and mesolimbic DA release [306] , suggesting that 7 receptors may not be involved in the alcohol-induced reward process. Given the apparent lack of actions of DH E or MLA on alcohol-induced behavioral and neurochemical effects, several possibilities can be argued, namely that too low doses of DH E and MLA were used in those studies or poor brain bioavailability in the case of MLA, differential nAChR subunit(s) are involved in the process [307] , or that nAChR desensitization is important for the effects of nicotine. On the other hand, similar doses of DH E or MLA were found to block nicotine-induced DA responses [306] . It is possible that the DA mediated responses induced by nicotine and ethanol are different with respect to the involvement of nAChR subunit composition [307] . Local administration of -CtxMII, a 16 amino acid-peptide and 6 nAChR ligand [284] into the VTA has been shown to decrease DA release in the nucleus accumbens, ethanol drinking and locomotor activity in rodents [307] . However, taken together, these results indicate that nAChRs are likely to be involved in both behavioral and neurochemical effects of alcohol and support the strong link the between nicotine addiction and alcoholism in humans. Thus nAChRs could also be important targets for therapeutic management of alcohol addiction.
Methamphetamine Addiction
Nicotinic receptor ligands and or nicotinic cholinergic transmission have been implicated in psychostimulant addiction. For example, methamphetamine-seeking behavior (craving) in rats was found to be attenuated by repeated nicotine administration for five days during methamphetamine withdrawal and suggesting the inactivation of nicotinic cholinergic neuron in methamphetamine seeking behavior [315] . Furthermore, systemic nicotine administration and donepezil, an acetylcholinesterase inhibitor, was found to attenuate reinstatement of methamphetamine-seeking behavior [316] . These results suggest that activation of nAChRs is critical in regulating methamphetamine addiction. Lobeline, a nAChR ligand and its synthetic analogs have been shown to attenuate amphetamine or methamphetamine self-administration in rodent model [317] [318] [319] . Lobeline has also been found to have high affinity for 4 2 nAChR subtypes [320, 321] and has been considered variously as an agonist, partial agonist, or antagonist at nAChRs [320] [321] [322] [323] . Neurochemical assays showed that lobeline attenuates amphetamine-evoked endogenous DA release in brain striatal slices [318] . Additionally, in DA release assays, lobeline has also been shown to act as an antagonist at 4 and 6* nAChRs [321] . In behavioral assays, lobeline and related analogs were reported to block the discriminative-stimulus properties of methamphetamine [321, 324] or decrease methamphetamine selfadministration [319] . Taken together, this behavioral and neurochemical evidence suggests that nAChRs are a potential target for the management amphetamine and methamphetamine mediated addictive behavior.
Cocaine Addiction
As reported with alcohol and methamphetamine, agonists and antagonists of nAChRs have been demonstrated to modulate cocaine-induced behavioral and neurochemical effects in humans and rodent models. Mecamylamine has been found to block cue-induced craving for cocaine [325] . Additional neurobehavioral studies suggest that administration of mecamylamine decreases cocaine effects in place preference paradigm [326] or cocaine-induced behavioral sensitization [327] . Furthermore, pretreatment with mecamylamine reduces cocaine self-administration in rodent models [328] [329] [330] , suggesting involvement of nAChRs in cocaine seeking behavior. Moreover, in rodent models, lobeline has been found to block discriminative-stimulus properties of cocaine [318, 324] . Consistent with behavioral evidence, it is reported that systemic application of mecamylamine or MLA, along with DH E diminishes cocaine-induced increase in mesolimbic DA release [331] . Overall, these results support the hypothesis that there may be a potential involvement of nAChRs in cocaine mediated addictive behavior. Hence nAChRs could be important target for developing pharmacotherapy in the management of cocaine addiction in humans.
Opiate Addiction
Evidence suggests that effects of morphine are associated with the brain cholinergic transmission [332] [333] [334] . Furthermore, actions of acetylcholine at nAChRs are thought to be critical for the modulation of opioid withdrawal signs [335] . Like other forms of drug addictions, nAChRs have been implicated as important target for medication development for the management of opiate addiction [336, 337] . For example, 18-Methoxycoronaridine (18-MC), a synthetic iboga alkaloid has been found to reduce morphine self-administration [338] ; attenuates several signs of morphine withdrawal in rats [339] . A number of studies indicate that effects of 18-MC on morphine self-administration and morphine-induced changes in mesolimbic DA function are associated with the blockade of 3 4 nAChRs [335, 339, 340] and these receptors are localized in brain habenula and interpeduncular nucleus [31, 341] . Similarly, non-selective 3 4 nAChR antagonists such as mecamylamine, dextromethorphan and bupropion were found to reduce morphine selfadministration and withdrawal syndrome [342] . Taken together, these studies suggest that brain nAChRs, specifically 3 4 subtype could be critical target for novel pharmacotherapy of opiate addiction.
CHALLENGES IN NICOTINE RECEPTOR-BASED RESEARCH
Clearly much progress has been made in recent years regarding which nAChR subtypes are most likely to be associated with nicotine addiction in animal models. However, there are still many big questions that need to be addressed, some of which are so fundamental that they serve to indicate that the distance we have yet to go is almost certainly farther than the great distance we have come so far. Such basic questions include asking whether nicotine addiction is associated with behavioral motivation to activate nAChRs or to keep them desensitized, and to what degree the persistent presence of nicotine in the brains of smokers down-regulates or desensitizes endogenous ACh-mediated signaling.
All of the detailed work done to understand the cholinergic signal at the neuromuscular junction fails to inform us of the nature of the cholinergic signal presented to nAChRs in the brain: how high ACh concentrations rise, how long do high levels persist, and to what degree those signals vary between brain regions (e.g. the mesolimbic system and the hippocampus). Once released, ACh is subsequently converted to choline, which we know is an agonist for the 7 receptors in brain. However, we do not know if there is really a role for choline in nAChR signaling in the brain in regard to 7. There will be fluctuating levels of choline associated with ACh release and metabolism that will add to the steady-state levels of choline in the cerebro-spinal fluid. It is unclear whether these qualitatively different choline signals predominantly activate or desensitize 7 receptors in the brain.
While in recent years we have gained a substantially better understanding of the nAChRs associated with nicotine self-administration in humans, we are still unsure which are the key nAChRs associated with the positive cognitive effects of nicotine and whether they are distinct from those associated with addiction. The question of which nAChR subtypes are most likely to be involved with the positive cognitive effects of nicotine is somewhat controversial, but there is good evidence for the involvement of both 7 and 4 2* type receptors [343] . Additional components, such as cognitive, arousal, attentional and memory processes, likely also contribute significantly to the phenomenon of addiction. If the receptors are different for cognitive and addicting effects, it will be important to know more about the effects of self-administered nicotine on both the activation and desensitization of those separate receptor populations. While we have begun to learn how chronic nicotine can change nAChR expression in the brain, we do not know how long the nicotine-induced changes in nAChR expression in the brain persist following the cessation of nicotine selfadministration or to what degree the persistence of nicotineinduced changes in nAChR expression relate to withdrawal and/or relapse.
With all these questions to be studied, the potential for new discoveries in this field is enormous. For example, in the future we may learn the relationship between nAChR and depression, and whether that is amplified or diminished by the use of nicotine in psychoactive amounts and/or withdrawal. Will targeting the nAChR in the brain become a new treatment approach for depression, or alternatively does the relationship between nAChR and depression only develop as a consequence of nicotine addiction?
SUMMARY AND CONCLUSIONS
Data suggest that brain nAChRs are critical targets for the development of new pharmacotherapies to treat nicotine and other forms of drug addictions. Notwithstanding progress that has been made, given the diversity of nAChR subtypes and the complex regulation of their function by nicotine and potential therapeutic agents, we remain with the tasks of identifying the subtype-specific nAChR targets, defining mechanisms of action, and determining if selectivity is the needed pharmacological optimum for the balance of maximal effective treatment with minimal adverse consequences. A set of preclinical behavioral models is available to support the requisite studies, however one needs to be aware that these models predict elements of the addictive process but have yet to be validated as predictive for medication effectiveness in humans. Likewise some neurochemical elements consequent to nAChR binding have been elucidated, but the scope of such research has to-date been limited largely to the midbrain dopamine system. Nonetheless, on balance, the impressive progress that has been made in the nAChR field has advanced us well beyond the classical model of the nAChR of the neuromuscular junction. These improved insights will yield molecular tools for model validation and as platforms for therapeutic development. 
